Basic Information
Pepaxti
Regulatory Information
EMEA/H/C/005681
August 17, 2022
5
October 24, 2024
Company Information
Sweden
Luntmakargatan 46, vån 7 111 37 Stockholm
Oncopeptides Ab
Active Substances Detail
EMA Resources
Detailed Information
Therapeutic Indication
### Therapeutic indication Pepaxti is indicated, in combination with dexamethasone, for the treatment of adult patients with multiple myeloma who have received at least three prior lines of therapies, whose disease is refractory to at least one proteasome inhibitor, one immunomodulatory agent, and one anti-CD38 monoclonal antibody, and who have demonstrated disease progression on or after the last therapy. For patients with a prior autologous stem cell transplantation, the time to progression should be at least 3 years from transplantation (see section 4.4).
Overview Summary
Pepaxti is a medicine used to treat adults with multiple myeloma (a cancer of the bone marrow) when the cancer has not responded to previous treatments (refractory). It is used in combination with dexamethasone (an anti-inflammatory medicine) in adults who have received at least three prior therapies, including an immunomodulatory agent, a proteasome inhibitor and an anti‑CD38 antibody, and whose disease has worsened since the last treatment. For patients who have had an autologous stem cell transplantation (a procedure where the patient’s bone marrow is cleared of cells and replaced by stem cells from the patients themselves), Pepaxti can be used if the time from transplantation to when the cancer comes back is at least three years. Multiple myeloma is rare, and Pepaxti was designated an ‘orphan medicine’ (a medicine used in rare diseases) on 19 March 2015. Further information on the orphan designation can be found here: [https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-15-1463](/en/medicines/human/orphan-designations/eu-3-15-1463) Pepaxti contains the active substance melphalan flufenamide.